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Purpose: To describe the clinical and genetic findings in two consanguineous families with Best vitelliform macular
dystrophy (BVMD) and homozygous mutations in the bestrophin-1 (BEST1) gene.
Methods: Ophthalmologic examination was performed in eight members of two families originating from Spain and
Denmark. Mutation screening was performed using the Vitelliform Macular Dystrophy mutation array from Asper
Biotech, and by the directed genomic sequencing of BEST1.
Results: Two homozygous mutations were detected in these families. Mutation c.936C>A (p.Asp312Glu) has been
reported previously in a Danish family; here, we describe four additional individuals in this family demonstrating findings
compatible with a severe dominant BVMD, albeit with reduced penetrance in heterozygotes. In the Spanish family, a
novel homozygous missense mutation in exon 4, c.388 C>A (p.Arg130Ser), was identified in the siblings. Homozygous
siblings demonstrated evidence of multifocal vitelliform retinopathy, whereas heterozygous family members presented
findings ranging from isolated reduction of the electrooculogram Arden ratio to normal values on all clinical parameters.
Conclusions: As demonstrated in these consanguineous families, a great clinical variability is associated with homozygous
mutations in BEST1, ranging from severe dominant BVMD with reduced penetrance in heterozygotes to autosomal
recessive bestrophinopathy.
Bestrophin-1 is the product of the gene BEST1. This
protein  is  mainly  expressed  in  the  basolateral  plasma
membrane  of  the  retinal  pigment  epithelium  (RPE)  [1],
although  some  expression  has  also  been  detected  in  the
kidney, brain, spinal cord, and testis [2,3]. Bestrophin-1 has
sequence similarity with the RFP protein family, so named for
its  highly  conserved  arginine  (R),  phenylalanine  (F),  and
proline (P) amino acid sequence motif. This protein contains
several  domains  with  a  high  degree  of  evolutionary
conservation  [2].  Protein  bestrophin-1,  consisting  of  585
amino acids, is required for normal ocular development [4,
5]. Its function remains unclear and has been proposed to act
as a Cl− channel activated by intracellular Ca2+ and/or as a
channel regulator [6].
BEST1 has been mapped on the long arm of chromosome
11q12-q13, and was first identified in 1998 [3]. At least 253
mutations  have  been  described  in  this  gene
(VMD2_database),  and  these  have  been  related  to  four
clinically distinguishable degenerative human eye diseases,
collectively referred to as bestrophinopathies. The clinical
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features in patients with mutations in BEST1 seem to cluster
into  at  least  four  major  categories,  as  reviewed  by
Marmorstein et al. [6]: Best vitelliform macular dystrophy or
Best disease (BVMD, OMIM 153700), autosomal dominant
vitreoretinochoroidopathy  (OMIM  193220),  autosomal
recessive  bestrophinopathy  (ARB,  OMIM  611809),  and
adult-onset  vitelliform  macular  degeneration  (OMIM
608161). Recently, missense mutations in BEST1 have been
implicated in retinitis pigmentosa (RP) [7].
Burgess et al. [8] were the first to describe a distinct
retinal  disorder  they  designated  as  autosomal  recessive
bestrophinopathy  (ARB).  Characteristics  of  the  disorder
included  central  visual  loss  with  progressive  decrease  in
visual  acuity,  a  characteristic  retinopathy,  an  absent
electrooculogram  (EOG)  light  rise,  and  a  reduced
electroretinogram (ERG). None of the patients showed the
vitelliform  lesions  typical  of  Best  disease,  but  showed  a
diffuse  irregularity  of  the  reflex  from  the  RPE,  including
dispersed  punctate  flecks.  All  patients  showed  an
accumulation of fluid within and/or beneath the neurosensory
retina in the macula. All patients were hyperopic, and three
patients from two families also had angle-closure glaucoma
[8].
To date, only 13 patients from 11 different families have
been described [7-14] with biallelic mutations in BEST1. Most
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1607of these mutations have been described as missense mutations,
except for a homozygous R200X nonsense or stop mutation
(in two patients from the same family) and a heterozygous
L88del17  deletion  (in  one  patient).  In  addition,  two
individuals from a single family were described as having
atypical  BVMD  [15],  although  the  description  of  the
phenotype is suggestive of ARB. Furthermore, a large survey
by Kinnick et al. has recently identified 11 other patients with
autosomal  recessive  macular  dystrophy  and  a  range  of
different  biallelic  mutations  in  BEST1,  including  intronic
mutations and deletions [16].
In the present study, we describe two consanguineous
families with homozygous mutations in BEST1, being the
sixth  and  seventh  patients  characterized  until  now  with
homozygous mutations in this gene.
METHODS
Patients: We report two consanguineous (first-degree cousin)
families. A Spanish family (S) with two siblings affected (a
4-year-old girl and a 9-year-old boy) and a Danish family with
two siblings affected (a 6-year-old and a 10-year-old boy).
The individual clinical details are summarized in Table 1, and
pedigrees  are  shown  in  Figure  1.  The  recruitment  of  the
Spanish patients and relatives was performed through the
Servicio  de  Oftalmología  of  the  Complejo  Hospitalario
Universitario de Vigo (Pontevedra, Spain).
Clinical  and  molecular  genetic  findings  in  two  other
individuals from the Danish family (DII) have been described
previously [14]. This molecular study adhered to the tenets of
the Helsinki Declaration. Informed consent was obtained from
all patients and relatives after explanation of the nature and
possible consequences of the study. Approval for the study
was obtained from an ethics committee. The Spanish control
group consisted of 50 unrelated normal individuals provided
by the Complejo Hospitalario Universitario de Vigo.
Clinical evaluation:
Spanish  family—Clinical  evaluation  consisted  of
Pigassou and Snellen best-corrected visual acuity test, slit
lamp biomicroscopy, extrinsic ocular motility, retinography,
fluorescein  angiography  (AGF),  fundus  autofluorescence
(FAF), optical coherence tomography (OCT), visual evoked
potentials (VEP), EOG, and full-field ERG. The Pigassou test
was used to evaluate the female sibling’s visual acuity (under
five years old) and Snellen test was used to value the male
sibling’s  visual  acuity  (over  five  years  old).  Fundus
photography and AGF were recorded using the Topcon TRC
SOIA Retinal Camera together with a HAD Color Video
Camera connected to a Topcon Digital Imagenet 2000 System
(Newbury Berkshire, UK). Autofluorescence was recorded
using the Carl Zeiss Meditec AG FF 450 plus a Dolphin IR
Digital Interface (Carl Zeiss Meditec, Jena, Germany). OCT
was performed using a Cirrus TM HD-OCT Spectral Domain
together with a scanning laser fundus camera (Carl Zeiss®).
ERGs, EOGs, and visual evoked responses were recorded
using  a  Medelec  Synergy  (Oxford®  Instruments,  Oxon,
England).
Danish family—Multifocal ERGs were recorded using
a visual evoked response imaging system (VERIS 4; EDI, San
Mateo, CA), as described previously [17].
In family DII, fundus morphology was examined using a
combined OCT and scanning laser fundus camera (Spectralis
HRA-OCT, Heidelberg Engineering, Heidelberg, Germany).
EOG was recorded with a Nicolet analysis system (Nicolet
Biomedical  Instruments,  Madison,  WI),  as  described
previously [18,19].
Molecular methods: Molecular genetic findings in two of the
individuals  from  the  Danish  family  have  been  described
previously [14]. In this study, four additional family members
were  examined  (Figure  1).  Blood  was  collected  by
venipuncture  from  members  of  the  Spanish  family,  and
genomic  DNA  was  isolated  with  Flexi  Gene  DNA  Kit
(Qiagen, Hilden, Germany) following the instructions of the
manufacturer for isolation of DNA from 4 to 14 ml whole
blood.
The DNA samples were analyzed using the Vitelliform
Macular Dystrophy (BEST-VMD) mutation array from Asper
Biotech  (Asper  Ophthalmics,  Tartu,  Estonia).  The  BEST-
VMD test has been developed for screening 138 mutations/
SNPs  from  the  BEST1  (VMD2)  gene.  This  array  utilizes
Arrayed Primer Extension technology, first described in 1996
[20].
The 11 exons of the BEST1 gene were amplified by PCR
in  a  MJ  MiniTM  Gradient  Thermal  Cycler  (Bio-Rad,
Hercules,  CA).  The  primers  used  (Table  2)  have  been
previously  described  [2].  The  sequencing  reactions  were
precipitated,  dried  and  analyzed  on  an  AB  3130  genetic
analyzer (Applied Biosystems, Foster City, CA). Sequence
data  was  aligned  to  reference  GenBank  cDNA  sequence
NG_009033 and examined for sequence variations. Detected
mutations  were  confirmed  by  a  second  independent  PCR
reaction  and  were  identified  in  both  forward  and  reverse
strands.
We used two sequence homology–based tools—Protein
Basic  Local  Alignment  Search  Tool  (BLASTP)  and
Polymorphism  Phenotype  (PolyPhen)—to  predict  the
potential impact of two amino acid substitutions.
RESULTS
Spanish family: Two siblings, a 4-year-old female and a 9-
year-old male, and their parents were studied. Both siblings
had vitelliform macular dystrophy. The female presented a
pseudohypopyon in the right eye and predominantly atrophic
changes in the left eye (Figure 2). Visual acuity was 0.8 in
both eyes; the patient was moderately hyperopic and had
accommodative esotropia. OCT demonstrated a neurosensory
retinal  detachment,  typical  of  this  stage  (Figure  2).
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1609Autofluorescence  imaging  showed  hyperautofluorescent
lesions that represented the deposit of vitelliform material in
the  posterior  pole  and  peripheral  retina,  and
hypoautofluorescent  lesions  that  represented  RPE  atrophy
(Figure 2). The EOG Arden ratio was reduced (OD:1.00/OS:
1.12), while full-field ERG and VEP were normal.
The male presented perimacular scars in both eyes. By
AGF,  there  were  multiple  hypofluorescent  discs  in  the
peripheral  retina  caused  by  the  deposition  of  vitelliform
material. The OCT showed cystic degeneration of the sensory
retina,  typical  of  advanced  stages  of  retinal  dystrophies
(Figure 3). In this case, not only the EOG Arden ratio (OD:
1.03/OS:1.12),  but  also  the  ERG  was  altered  (reduced
amplitudes of the a and b waves). Nevertheless, the patient
had  good  visual  acuity  (0.6  in  both  eyes).  The  VEP  was
normal. The mother presented with a slightly reduced EOG
Arden ratio in the right eye (OD:1.73/OS:2.00), but normal
fundoscopy, and clinical examination of the father was normal
on all investigations (retinography, FAF, OCT, VEP, EOG,
and ERG).
Screening  for  previously  reported  BEST1  mutations
using the BEST-VMD array was negative. Nevertheless, this
array has a great potential for a first screening diagnosis as
some  of  the  disease-causing  mutations  are  recurrent.
Sequencing of BEST1 in the affected siblings revealed a novel
homozygous missense mutation in exon 4, c.388C>A. This
mutation  replaces  arginine  with  serine  at  codon  130
(p.Arg130Ser).  Additional  non-disease-causing
Figure 1. Cosegregation analysis of the
mutations. A: Pedigree of the Spanish
family and segregation analysis of the
p.Arg130Ser mutation of BEST1. The
siblings  were  homozygous  for
p.Arg130Ser  while  the  parents
demonstrate  heterozygosity  for  the
mutation.  Double  lines  indicate  first
degree cousins and symbols with a dot
inside indicate carry individuals for the
mutation.  B:  Pedigree  of  the  Danish
family with BEST1 mutations, modified
from Schatz et al. [12]. In the present
study, four additional family members
were examined, marked by an asterisk.
M/+  denotes  heterozygosity  for
mutations  in  BEST1,  whereas  M/M
denotes homozygosity.
TABLE 2. OLIGONUCLEOTIDES FOR GENOMIC AMPLIFICATION AND SEQUENCING OF BEST1 GENE.
Exon Forward primer (5′-3′) Reverse primer (5′-3′) Tm
(°C)
Product size (pb)
1 AGCCCAACACCCTCCAAGAA AAGGTGCCCCAGGTGGACT 58 297
2 CCCTACAAACCCCCAATCG CTGGGAAGGATGTGGCTGG 62 272
3 AGTCTCAGCCATCTCCTCGC CAGGCTCCAGACAGGCCA 63 212
4 AGAAAGCTGGAGGAGCCGA AGGAATGGAAGATGGGTGGA 61 413
5 GCCATCCCTTCTGCAGGTT GTACAGACAGGGCTGCCGC 58 239
6 GGGGCAGGTGGTGTTCAGA CTAGGCTGGTGAGGCTGCC 62 150
7 TGATTTCAGGGTTCCCACCTAG AGCTGCCTGAGACGAGGATG 58 286
8 AGGGTTTACAGAGCCTCACCTG CATGGACCTTCCCCAAAGTG 62 158
9 CCTCCAAGTCATCAGGCACATA CTAGTGCAGGGGTCTGCCTAG 58 289
10A ACTGGCTCAGCCCTGCATC CAGGCTACTACAGTGCCCCAC 62 340
10B CCTTCAAGTCTGCCCCACTG GAACCAGGGGCACTGCA 62 417
11 GGGACCTTCCATACTTATGCTG TTCATCCCAAGACCT 61 492
Molecular Vision 2011; 17:1607-1617 <http://www.molvis.org/molvis/v17/a179> © 2011 Molecular Vision
1610Figure 2. Clinical evaluation of the female sibling from the Spanish family. Color fundus appearance photographs (A, B). The right eye shows
a typical pseudohypopyon stage with a deposit of yellowish vitelliform material in the lower half of the macular lesion. The left eye shows a
characteristic atrophic stage. Fluorescein angiography (AGF) shows a hyperfluorescence window defect due to atrophy of the retinal pigment
epithelium (RPE; C, D), and hypofluorescence due to a deposit of lipofuscin (C). Vitelliform lesions appear as areas of hyperautofluorescence
(E) and hypoautofluorescence (F) fundus autofluorescence (FAF). Optical coherence tomography (OCT) section of the pseudohypopyon
lesion shows a hyperreflective material beneath the retina in the right eye (G) and a neurosensory retinal detachment in the left eye (H). OD:
Right eye, OS: Left eye.
Molecular Vision 2011; 17:1607-1617 <http://www.molvis.org/molvis/v17/a179> © 2011 Molecular Vision
1611Figure 3. Clinical evaluation of the male sibling from the Spanish family. Color fundus appearance photographs showing perimacular scars
in both eyes (A, B). By fluorescein angiography (AGF), there are multiple hypofluorescent discs in the peripheral retina caused by the deposition
of vitelliform material. AGF also shows a hyperfluorescence window defect due to atrophy of the retinal pigment epithelium (RPE). Multiple
hypoautofluorescent lesions in the peripheral retina due to lipofuscin deposits on the fundus autofluoresence image (E, F). Optical coherence
tomography (OCT) showing RPE detachment and cystic degeneration of the sensory retina, typical of advanced stages of retinal dystrophies
(G, H). OD: Right eye, OS: Left eye.
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1612polymorphisms were also identified. The proband’s parents
were heterozygous for the c.388C>A mutation. The mutation
was absent in 50 healthy unaffected European controls.
Simulation  for  functional  changes  by  a  structure
homology-based method using the Polyphen program resulted
in classifying the Arg130Ser change as probably damaging
(Position-Specific  Independent  Counts,  PSIC02.615).
Arg130Ser is with high confidence supposed to affect protein
function or structure.
Multiple alignment of bestrophin-1 protein (BLASTP)
showed conservation of the regions that harbor the missense
variant p.Arg130Ser (Figure 4). The residue in position 130
is located in the N-terminal half of the protein, which shows
the highest evolutionary conservation [21,22].
Danish  family:  The  c.936C>A  transversion,  leading  to
p.Asp312Glu, is a novel mutation found in family DII, in
which the affected father was heterozygous while his affected
son III:7 was homozygous for this dominant mutation [14].
Amino acid 312 is located in a highly conserved region of
bestrophin, is perfectly preserved in different species, and
mutations in many amino acids flanking it cause Best disease,
adult-onset  vitelliform  macular  degeneration,  or  ARB.
Furthermore, a pathologically reduced EOG Arden ratio in the
presence of a normal full-field ERG in the heterozygous father
of family DII indicated that p.Asp312Glu is a disease-causing
mutation leading to AD Best disease [14].
The mutation was subsequently verified heterozygously
in the clinically unaffected mother II:1 (Figure 5) and son III:
4,  both  of  whom  showed  normal  fundi,  OCT,  and
autofluorescence,  but  whose  EOG  Arden  ratios  were
pathologically  reduced  (1.29/1.39  and  1.57/1.39,
respectively). The mutation was also found homozygously in
two clinically affected sons III:7 and III:8, of which the former
has been described recently by Schatz et al. [14]. The latter,
III:8,  showed  a  tiny  vitelliform  foveal  lesion,  which  was
visualized by OCT (Figure 6). EOG was not possible due to
the young age (six years old). The mutation p.Asp312Glu was
absent in the clinically unaffected daughter III:3.
DISCUSSION
Over 253 different BEST1 mutations have been described.
There is great phenotypic variability among patients carrying
these mutations, including those clinically diagnosed with
BVMD,  AVMD,  autosomal  dominant
vitreoretinochoroidopathy, RP, and ARB. Burgess clinically
described this last condition in five families with biallelic
mutations in the BEST1 gene [8].
In the current study, the clinical examination showed a
different  phenotype  in  the  two  siblings  from  the  Spanish
family and in at least one sibling from the Danish family. In
the  Spanish  family,  the  female  sibling  showed  macular
lesions,  typical  of  Best  disease,  and  hyperautofluorescent
lesions  in  the  posterior  pole  and  midperiphery.  The  male
sibling could be classified as exhibiting a late stage of Best
with perimacular scars, also featuring multifocal disease. In
the Danish family, the two homozygous boys demonstrated
evidence of multifocal vitelliform lesions, at least by FAF,
although the findings were subtle in the youngest boy III:8
and severe in III:3. In neither of them was it possible to obtain
an EOG.
Patients with biallelic mutations in BEST1 show a highly
variable phenotype [7-16]. In many cases, the phenotypes
described are associated with ARB; however, in other cases
these are more to similar to BVMD. To date, only a few
homozygous  cases  have  been  identified.  Bakall  et  al.  [9]
described a patient homozygous for the p.W93C mutation
whose disease was as severe as that reported for affected
family members heterozygous for the same mutation. This
differs from the study of Querques et al. [11], who reported
an individual homozygous for the p.R92C mutation with a
phenotype consistent with the diagnosis of multifocal BVMD,
considered more severe than that reported for heterozygotes.
Nevertheless, in the Spanish family, the parents heterozygous
for  p.Arg130Ser  were  clinically  unaffected  and  only  the
mother showed a slightly reduced EOG Arden ratio in the right
eye (OD: 1.73), which was considered nonpathological [23].
In  this  case,  unlike  Querques  et  al.’s  report,  the  correct
segregation  of  the  mutation  excludes  a  deletion  or
Figure 4. Multiple sequenced alignment
(Basic Local Alignment Search Tool) of
bestrophin-1 around the mutated residue
(p.Arg130Ser)  for  eight  species.  The
residues  at  position  130  are  highly
conserved.
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1613hemizygosity. In the Danish family, the heterozygous father
demonstrated  a  reduced  EOG  Arden  ratio  of  1.4  and  an
atypical  macular  degeneration  characterized  mainly  by
atrophy  [14].  The  mother  was  clinically  unaffected  and
presented an EOG Arden ratio of 1.29 and 1.39 in the right
and left eye, respectively. The pathology described in the
father  could  be  the  result  of  overlapping  ocular  entities;
however, a screening for mutations in ABCR was negative
[14].
In all these cases presented, the severity of the phenotype
seems  to  be  associated  to  the  homozygous  state  of  the
mutation in BEST1.
Burgess  et  al.  [8]  identified  another  two  individuals
homozygous (R200X) for BEST1 described as a typical ARB
phenotype, and finally Davidson et al. presented an affected
RP individual homozygous (L140V) for BEST1.
The review of the literature showed two cases that could
be  suspected  to  be  biallelic  for  BEST1.  Boon  et  al.  [24]
described  a  five-year-old  patient  with  a  mutation
(p.Lys194_Ala195insVal)  in  BEST1.  The  father  was
heterozygous  for  the  same  mutation,  displayed  no
abnormalities in eye examination, and had a normal EOG.
This case could involve a recessive inheritance where the
second  mutation  was  not  detected.  Caldwell  et  al.  [25]
described  an  eight-year-old  patient  heterozygous  for  the
p.E300D mutation, whose mother was also heterozygous for
this mutation but was clinically unaffected. It would be very
interesting to reinvestigate these cases and to establish the
segregation  in  these  families  to  define  the  dominant  or
recessive pattern of inheritance.
Many of the disease-causing mutations in BEST1 cause
Cl- channel dysfunction. The mutations located in the highly
acidic  region  of  the  C-terminus  render  bestrophin-1
nonfunctional as a Cl- channel, and these mutations may exert
dominant  negative  effects.  The  mutations  disrupt  the
interaction between the N and the C termini, and may disrupt
the bestrophin multimer. For mutations located between the
TM2  and  TM5  region,  including  p.Arg130Ser,  located  in
TMD3,  it  is  not  clear  how  the  mutations  affect  channel
function [26]. But whether or not the light peak is generated
by the putative bestrophin-1 Cl− channel is controversial, as
some patients (e.g., the Spanish family) with certain disease-
causing mutations have normal or nearly normal EOGs.
The pathological nature of the p.Arg130Ser mutation was
established by virtue of 1) its absence in 50 healthy unaffected
controls, 2) its cosegregation with disease in the family, 3) its
Polyphen PSIC score (2.615), which suggests that it may have
a functional impact, and 4) its affect on a conserved residue
of the TMD3 domain of bestrophin-1 in the two proposed
Figure 5. Clinical evaluation of patient II:1 from the Danish family. Patient II:1 showed normal fundus appearance (A), multifocal-
electroretinograms (ERGs; B), and optical coherence tomography (OCT; C).
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1614models for the topological organization of this protein [21,
22].
This change is located outside of the different clusters of
hot-spots defined for BVMD (6–30, 80–104, 221–243, and
293–312 amino acid regions) [27]. For mutations p.R141H,
p.A146K,  and  p.P152A  located  in  the  surroundings  of
p.Arg130Ser, a reduced measurable basal Cl- current has been
demonstrated, indicating no dominant negative effect. As the
heterozygous  parents  are  unaffected,  the  missense  change
p.Arg130Ser would not be expected to have a dominant effect.
In the Danish family with the c.936C>A transversion leading
to p.Asp312Glu, there were three heterozygous individuals.
The  heterozygous  father  had  an  atypical  central  foveal
bilateral atrophy [14] with reduced EOG Arden ratio, whereas
the  heterozygous  mother  and  heterozygous  brother  had  a
normal fundus, OCT, and FAF, but the EOG Arden ratio was
in the pathological range. It has been proposed by Hartzell et
al. [23] that the association of bestrophin-1 with accessory
subunits could alter their biophysical properties. Mutations in
accessory subunits, or modifier genes, could influence the
activity  of  bestrophin-1.  It  is  very  important  to  perform
functional studies that shed light on the activity of this mutated
protein.
The  p.Arg130Ser  and  p.Asp312Glu  changes  in  the
homozygous  state  could  confer  a  phenotype  similar  to
BVMD, more severe than that described by Burgess et al.
[8]  for  ARB.  The  varying  expression  and  incomplete
penetrance of this disease have been described by several
studies. Little is known about the exact mechanism of the
reduced  penetrance  and  variable  expression,  so  several
explanations remain possible.
As pointed out by Marmorstein and coworkers [6], if
ARB  is  a  true  null  phenotype,  it  would  be  predicted  to
resemble  a  severe  case  of  BVMD,  as  has  been  found  in
homozygous individuals in the Spanish family. On the other
hand,  in  the  Danish  family,  the  presented  information
Figure 6. Clinical evaluation of patient III:8 from the Danish family. Fundus appearance (A) and optical coherence tomography (OCT) showing
a tiny vitelliform foveal lesion (B).
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compatible  with  a  severe  dominant  BVMD,  albeit  with
reduced penetrance in heterozygotes.
In  summary,  we  present  evidence  of  great  clinical
variability associated with homozygous mutations in BEST1.
Other factors, genetic or environmental, could modulate the
phenotype  in  these  families,  since  the  retinopathy  in  the
presented  patients  is  not  identical  even  within  the  same
families.
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